Liquid blood tests for early esophageal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial studies how well “liquid biopsy” blood tests can work in people with newly diagnosed, operable esophageal cancer. It may help doctors monitor the cancer and guide treatment planning alongside standard care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re 18 or older
- You have a new diagnosis of esophageal cancer confirmed by pathology
- Your cancer is found only in the chest/region (not spread to distant sites)
- Your cancer type is squamous cell cancer or adenocarcinoma
- Your treatment plan involves a multidisciplinary team decision and surgery is planned after that team meeting
- You can sign consent to join the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving chemotherapy after surgery, based on a blood test that finds tiny bits of cancer DNA, can improve outcomes for people with esophageal squamous cell carcinoma. The blood test helps decide who might benefit from extra treatment.
This study tests a combination of chemotherapy, immunotherapy, and radiation for esophageal cancer that cannot be surgically removed. It also uses a simple blood test (ctDNA) to monitor your cancer's response throughout treatment.
This trial uses a blood test to track genetic changes in esophageal cancer over time. It aims to see if these changes can show how well treatment is working.
This trial tests whether a personalized treatment plan, chosen using a lab-grown model of your tumor, works better than standard therapy for esophageal cancer that can be surgically removed. It aims to find the most effective drugs for you before surgery.
This study will test whether special imaging dyes can help doctors see a protein called PD-L1 on esophageal cancer tumors. This might help guide treatment by showing whether immunotherapy drugs are likely to work.
This trial studies blood-based biomarkers to help doctors choose the best individualized surgical treatment for gastroesophageal junction adenocarcinoma. If you qualify, you’ll get standard care plus additional testing to see whether the blood results can guide surgery more precisely.
Hear when a new Esophageal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.